These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4568295)

  • 1. Hexamethylmelamine (NSC-13875) for acute leukemia and solid tumors in children.
    Dyment PG; Fernbach DJ; Sutow WW
    J Clin Pharmacol New Drugs; 1973; 13(2):111-3. PubMed ID: 4568295
    [No Abstract]   [Full Text] [Related]  

  • 2. Hexamethylmelamine (NSC-13875) in the treatment of advanced cancer.
    Wampler GL; Mellette SJ; Kuperminc M; Regelson W
    Cancer Chemother Rep; 1972 Aug; 56(4):505-14. PubMed ID: 5081594
    [No Abstract]   [Full Text] [Related]  

  • 3. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
    Stolinsky DC; Bogdon DL; Solomon J; Bateman JR
    Cancer; 1972 Sep; 30(3):654-9. PubMed ID: 5075351
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of the combination of hexamethylmelamine (NSC-13875) and methotrexate (NSC-740) in carcinoma of the lung.
    Weiss AJ; Wilson WL
    Cancer Chemother Rep; 1971 Jun; 55(3):299-302. PubMed ID: 5115850
    [No Abstract]   [Full Text] [Related]  

  • 5. Preliminary clinical evaluation of azapropazone in rheumatoid arthritis.
    Grennan DM; Watkins C; Kennedy AC
    Curr Med Res Opin; 1974; 2(2):67-71. PubMed ID: 4597571
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
    Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
    Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further experience with hexamethylmelamine (NSC-13875) in the treatment of carcinoma of the cervix.
    Stolinsky DC; Bateman JR
    Cancer Chemother Rep; 1973; 57(4):497-9. PubMed ID: 4586957
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).
    Luce JK; Thurman WG; Isaacs BL; Talley RW
    Cancer Chemother Rep; 1970 Apr; 54(2):119-24. PubMed ID: 4334086
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase III study in lung carcinoma comparing hexamethyl-melamine (NSC 13875) to dibromodulcitol (NSC 104800) 1,2.
    Wilson WL; Ryzin JV; Weiss AJ; Frelick RW; Moss SE
    Oncology; 1975; 31(5-6):293-309. PubMed ID: 174041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in patients with gastrointestinal carcinoma.
    Moertel CG; Reitemeier RJ; Hahn RG; Schutt AJ
    Cancer Chemother Rep; 1970 Dec; 54(6):471-3. PubMed ID: 4946016
    [No Abstract]   [Full Text] [Related]  

  • 11. L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia.
    Leventhal BG; Skeel RT; Yankee RA; Henderson ES
    Cancer Chemother Rep; 1970 Feb; 54(1):47-51. PubMed ID: 4945997
    [No Abstract]   [Full Text] [Related]  

  • 12. 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of advanced acute lymphocytic leukemia in children.
    Finklestein JZ; Albo V; Ertel I; Karon M; Hammond D
    Cancer Chemother Rep; 1972 Aug; 56(4):523-6. PubMed ID: 4507686
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase I clinical trial with alpha 1,3,5- triglycidyl-s-triazinetrione (NSC-296934).
    Piccart M; Rozencweig M; Dodion P; Cumps E; Crespeigne N; Makaroff O; Atassi G; Kisner D; Kenis Y
    Eur J Cancer Clin Oncol; 1981 Dec; 17(12):1263-6. PubMed ID: 7200026
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial clinical trials with 1,1-diphenyl-2-propynyl cyclohexanecarbamate (NCS-112682).
    Luce JK; Bodey GP
    Cancer Chemother Rep; 1970 Apr; 54(2):131-4. PubMed ID: 4946003
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of hexamethylmelamine in refractory Hodgkin's disease, other lymphomas, and chronic lymphocytic leukemia.
    Omura GA; Broun GO; Papps J; Birch R
    Cancer Treat Rep; 1981; 65(11-12):1027-9. PubMed ID: 6794907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase-I study of alpha-1,3,5-triglycidyl-s-triazinetrione (NSC 296934).
    Dombernowsky P; Lund B; Hansen HH
    Cancer Chemother Pharmacol; 1983; 11(1):59-61. PubMed ID: 6883626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours.
    European Organization for Research on the Treatment of Cancer, Clinical Screening Group
    Br Med J; 1973 Jul; 3(5873):199-202. PubMed ID: 4578134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute leukemia with 5-azacytidine (NSC-102816).
    McCredie KB; Bodey GP; Burgess MA; Gutterman JU; Rodriguez V; Sullivan MP; Freireich EJ
    Cancer Chemother Rep; 1973; 57(3):319-23. PubMed ID: 4127393
    [No Abstract]   [Full Text] [Related]  

  • 19. [A clinical study of N-nitrosomethylurea].
    Vermel' EM; Korman NP; Milonov BV; Evseenko LS; Orlova RS
    Vopr Onkol; 1970 May; 16(5):31-7. PubMed ID: 4915916
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical evaluation of hexamethylmelamine (NSC-13875).
    Bergevin PR; Tormey DC; Blom J
    Cancer Chemother Rep; 1973 Feb; 57(1):51-8. PubMed ID: 4704103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.